About
Enabling Therapeutic Application of Chimeric Antigen Receptor T Cells in Solid Tumors
CTG Pharma's solution enables chimeric antigen receptor (CAR) T therapy for HER2-positive solid tumors while mitigating toxicity and on-target off-tumor reactions. CTG Pharma's solutions include a library of 65,000 promoters that enable safer CAR T for the treatment of solid tumors, applicable to any CAR and suitable for a variety of tumor micro-environment conditions. CTG Pharma aims to create a broadly applicable platform to enhance the safety and efficacy of a variety of human CAR T therapies requiring regulation of CAR expression. The platform is composed of a rationally designed library of 65,000 different switches, for minimal immune response in healthy tissues and maximum expression of the CAR specifically in the tumor surroundings. It is a highly sensitive system that integrates unique signals from the solid tumor microenvironment for the regulation of CAR expression. The company's first line of products is HER2-positive cancers.
Identity
| Name | CTG Pharma |
|---|---|
| Slug | ctg-pharma |
| Type / kind | startup |
| Crunchbase ID | ctg-pharma |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Kjhg4sJDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Sep 2022 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Rehovot |
| HQ address | HaMada 8, Rehovot, Israel |
Web & social
| https://www.linkedin.com/company/42122350 |
Classifications
Funding
| Total raised | $2.0M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}